Home|Journals|Articles by Year|Audio Abstracts
 

Research Article

ECB. 2021; 10(4): 237-241


SIMULTANEOUS QUANTIFICATION of MINOXIDIL and FINASTERIDE in BULK and PHARMACEUTICAL DOSAGE FORM by RP-HPLC METHOD

Patel J., Tandel J., Chhalotiya U., Patel K..




Abstract

A strategic specific and sensitive quantitative analysis of Minoxidil and Finasteride has been developed by using HPLC with reliable, precise, and accurate result in bulk and marketed formulation. In this method Phenomenex C18 (250 mm × 4.6 mm, 5 μm) column was used as stationary phase and a composition of methanol: water (85:15 v/v) was used as mobile phase. An isocratic elution programming has been done at a flow rate of 1 mL min-1. The eluted analytes show appreciable absorbance at 223 nm. The proposed RP-LC method was validated according to ICH guidelines. The retention time of Minoxidil and Finasteride was found to be 3.15 min and 4.36 min respectively. The method was found to be linear over a range of 6 – 54 µg mL-1 for Minoxidil and 0.2-1.8 µg mL-1 for Finasteride. The percentage recovery was found to be 99.88-100.85 % for Minoxidil and 99.99-100.33 % for Finasteride. The proposed reverse phase LC method has potential qualitative as well as quantitative applications for simultaneous estimation of Minoxidil and Finasteride in bulk and pharmaceutical dosage form.

Key words: Finasteride; ICH guideline; Minoxidil; RP-HPLC; Validation






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.